More subjects on NeuroAiD™ improved to functional independence compared to placebo among subjects receiving rehabilitation up to 3 months after an acute ischemic stroke. The larger treatment effect of ...

With its targeted multimodal approach, NeuroAiD™II offers a broad range of therapeutic benefits to TBI patients. NeuroAiD™II was well-tolerated by TBI patients with a favourable safety profile.

The MarketWatch News Department was not involved in the creation of this content. Moleac is pleased to announce that NeuroAiD(TM)II has been awarded Gold accreditation by Empowered By Evidence.

SATURN study aimed at assessing the safety and effects of a 6-month course of NeuroAiD (MLC601/MLC901) to augment functional and motor recovery after severe spinal cord injury (SCI). NeuroAiD was safe ...

Patients who were taking NeuroAiD at acute stage had an 11 % increase in the odds being able to perform daily activities at the end of three months SINGAPORE, July 3, 2013 /PRNewswire/ -- NeuroAiD, a ...

-- The odds of functional independence defined as a modified Rankin Score (mRS) </= 1 were significantly increased at 6 months and persisted up to 18 months after stroke in the NeuroAiD™ group. Moleac ...

SINGAPORE, Feb. 4, 2026 /PRNewswire/ -- This recognition reflects the robust clinical evidence supporting NeuroAiD™II, as well as the uniqueness of its formulation, the rigour of its manufacturing, ...

SATURN study aimed at assessing the safety and effects of a 6-month course of NeuroAiD (MLC601/MLC901) to augment functional and motor recovery after severe spinal cord injury (SCI). NeuroAiD was safe ...